source
- AstraZeneca puts $2 billion into Summit Therapeutics and partners to test ivonescimab with its oncology pipelineAstraZeneca announced a $2 billion equity investment in Summit Therapeutics, acquiring roughly 109,000 shares of convertible preferred stock. The deal will give AstraZeneca about a 12% stake in Sum…
- Curium gains FDA nod for Bexlutry as it eyes challenge to Novartis radioligand therapiesCurium recently received FDA approval for its radiopharmaceutical Bexlutry, positioning it as a direct competitor to Novartis’ Lutathera. The biotech is also in discussions with the FDA about fili…